NCT00267800

Brief Summary

The cause of most interstitial lung diseases (ILDs) is still unknown. Further research, for example to determine predisposing genetic factors, is therefore needed. A database with relevant clinical data and DNA/serum samples of ILD patients could facilitate future research on the cause of ILDs.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
100,000

participants targeted

Target at P75+ for all trials

Geographic Reach
1 country

4 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 19, 2005

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 21, 2005

Completed
11 days until next milestone

Study Start

First participant enrolled

January 1, 2006

Completed
Last Updated

August 8, 2008

Status Verified

December 1, 2005

First QC Date

December 19, 2005

Last Update Submit

August 7, 2008

Conditions

Interstitial Lung Diseases

Keywords

Lung disease, InterstitialSarcoidosisPulmonary fibrosis

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Diagnosis of an ILD, as stated by the American Thoracic Society (ATS)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (4)

St. Antonius Hospital

Nieuwegein, 3435CM, Netherlands

Location

Diakonessenhuis

Utrecht, 3508 TG, Netherlands

Location

Mesos Medisch Centrum

Utrecht, 3527 CE, Netherlands

Location

UMC Utrecht

Utrecht, 3584 CX, Netherlands

Location

Related Publications (2)

  • Drent M, Wijnen PA, Jessurun NT, Harmsze AM, Bekers O, Bast A. Drug-Gene Risk Stratification in Patients with Suspected Drug-Induced Interstitial Lung Disease. Drug Saf. 2024 Apr;47(4):355-363. doi: 10.1007/s40264-024-01400-0. Epub 2024 Mar 9.

    PMID: 38460070DERIVED

  • Jessurun NT, Drent M, Wijnen PA, Harmsze AM, van Puijenbroek EP, Bekers O, Bast A. Role of Drug-Gene Interactions and Pharmacogenetics in Simvastatin-Associated Pulmonary Toxicity. Drug Saf. 2021 Nov;44(11):1179-1191. doi: 10.1007/s40264-021-01105-8. Epub 2021 Oct 4.

    PMID: 34606062DERIVED

MeSH Terms

Conditions

Lung Diseases, InterstitialSarcoidosisPulmonary Fibrosis

Condition Hierarchy (Ancestors)

Lung DiseasesRespiratory Tract DiseasesLymphoproliferative DisordersLymphatic DiseasesHemic and Lymphatic DiseasesHypersensitivity, DelayedHypersensitivityImmune System DiseasesFibrosisPathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • J.M.M. van den Bosch, M.D.

    St. Antonius Hospital

    PRINCIPAL INVESTIGATOR

  • J.C. Grutters, M.D.

    St. Antonius Hospital

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Sponsor Type
OTHER

Study Record Dates

First Submitted

December 19, 2005

First Posted

December 21, 2005

Study Start

January 1, 2006

Last Updated

August 8, 2008

Record last verified: 2005-12

Locations

NL(4)